Tags: Drug.
ANG1005 is a promising chemotherapy drug that was developed by a biotechnology company located in Montreal Canada known as Angiochem Inc. This drug is inserted intravenously and is currently in early clinical stages of development and dose escalation. However ANG1005 consists of a 19 amino acid long peptide vector known as Angiopep that is conjugated to a taxane derivative involved in mitotic inhibition known as paclitaxel.